BAL
MCID: MXD050
MIFTS: 43

Mixed Phenotype Acute Leukemia (BAL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Mixed Phenotype Acute Leukemia

MalaCards integrated aliases for Mixed Phenotype Acute Leukemia:

Name: Mixed Phenotype Acute Leukemia 12 52 15
B- and T-Cell Mixed Leukemia 12 17
Acute Leukemia of Indeterminate Lineage 52
Acute Leukemia of Undetermined Lineage 52
Acute Leukemia of Ambiguous Lineage 52
Undifferentiated Acute Leukemia 52
Leukemia, Biphenotypic, Acute 43
Mixed Lineage Acute Leukemia 52
Biphenotypic Acute Leukaemia 29
Acute Biphenotypic Leukemia 52
Biphenotypic Acute Leukemia 52
Aml with Lymphoid Markers 52
All with Myeloid Markers 52
Hybrid Acute Leukemia 52
Mpal 12
Bal 52

Classifications:



External Ids:

Disease Ontology 12 DOID:9953
MeSH 43 D015456
NCIt 49 C4673
SNOMED-CT 67 128818009 278453007
ICD10 32 C95.0
UMLS 71 C0023464

Summaries for Mixed Phenotype Acute Leukemia

Disease Ontology : 12 An acute leukemia that is characterized by the occurrance of more than one type of leukemia at the same time resulting from either the occurance of both acute lymphoblastic leukemia blasts and acute myeloblastic leukemia blasts at the same time or leukemic blasts that have features of both ALL and AML on the same cell.

MalaCards based summary : Mixed Phenotype Acute Leukemia, also known as b- and t-cell mixed leukemia, is related to tetrasomy 21 and leukemia. An important gene associated with Mixed Phenotype Acute Leukemia is MPO (Myeloperoxidase), and among its related pathways/superpathways are Endometrial cancer and Hematopoietic Stem Cells and Lineage-specific Markers. The drugs inotuzumab ozogamicin and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b lymphoblasts, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Mixed Phenotype Acute Leukemia

Diseases related to Mixed Phenotype Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)
# Related Disease Score Top Affiliating Genes
1 tetrasomy 21 30.3 DNTT ANPEP
2 leukemia 30.1 WT1 U2AF1 KMT2A FGFR1 DNMT3A ABL1
3 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 29.9 MPO KMT2A DNTT
4 childhood leukemia 29.8 MPO KMT2A ABL1
5 hypereosinophilic syndrome 29.6 MPO FGFR1 ABL1
6 leukemia, acute lymphoblastic 3 29.3 MPO KMT2A DNTT ANPEP ABL1
7 polycythemia vera 29.3 U2AF1 KDM4C DNMT3A ABL1
8 myelofibrosis 29.3 WT1 U2AF1 SETBP1 MPO FGFR1 DNMT3A
9 lymphoma 29.2 MSH6 FGFR1 DNTT CDH1 ANPEP
10 myeloid leukemia 29.1 WT1 U2AF1 MPO KMT2A DNMT3A CD33
11 lymphoblastic lymphoma 29.0 MPO KMT2A FGFR1 DNTT CD7
12 myeloma, multiple 28.7 U2AF1 KDM4C CDH1 CD33 ABL1
13 myeloid sarcoma 28.7 U2AF1 MPO KMT2A DNTT CD33 ANPEP
14 t-cell acute lymphoblastic leukemia 28.4 U2AF1 PHF6 KMT2A DNTT DNMT3A CD33
15 adult acute lymphocytic leukemia 28.4 CD7 CD33 ANPEP ABL1
16 acute leukemia 28.3 WT1 SETBP1 MPO KMT2A ERCC2 DNTT
17 acute promyelocytic leukemia 27.8 WT1 U2AF1 MPO KMT2A CD7 CD33
18 precursor t-cell acute lymphoblastic leukemia 27.8 MPO KMT2A DNTT CD7 CD33 ANPEP
19 pancytopenia 27.7 U2AF1 MPO LUC7L2 KMT2A CD7 CD33
20 myeloproliferative neoplasm 27.6 WT1 U2AF1 MPO LUC7L2 KMT2A FGFR1
21 leukemia, acute lymphoblastic 27.3 WT1 U2AF1 MPO KMT2A KDM4C DNTT
22 leukemia, chronic lymphocytic 27.2 U2AF1 KMT2A KDM4C DNTT DNMT3A CD7
23 leukemia, acute myeloid 27.2 WT1 U2AF1 SETBP1 PHF6 MPO LUC7L2
24 leukemia, chronic myeloid 26.5 WT1 U2AF1 SETBP1 MPO LUC7L2 KMT2A
25 hematologic cancer 26.4 WT1 U2AF1 LUC7L2 KMT2A KDM4C FGFR1
26 myelodysplastic syndrome 26.4 WT1 U2AF1 SETBP1 MPO LUC7L2 KMT2A
27 idiopathic acute eosinophilic pneumonia 11.3
28 sarcoidosis 1 10.8
29 lung disease 10.7
30 pulmonary fibrosis 10.6
31 pulmonary fibrosis, idiopathic 10.6
32 dermatitis 10.5
33 pulmonary sarcoidosis 10.5
34 extrinsic allergic alveolitis 10.5
35 bronchiolitis 10.5
36 mercury poisoning 10.5
37 wilson disease 10.4
38 pneumonia 10.4
39 bronchiolitis obliterans 10.4
40 interstitial lung disease 10.4
41 cytokine deficiency 10.4
42 cytogenetically normal acute myeloid leukemia 10.4 WT1 KMT2A
43 bronchitis 10.3
44 allergic hypersensitivity disease 10.3
45 endometrioid ovary carcinoma 10.3 WT1 MSH6
46 invasive aspergillosis 10.3
47 asbestosis 10.3
48 pulmonary tuberculosis 10.3
49 eosinophilic pneumonia 10.3
50 encephalopathy 10.3

Graphical network of the top 20 diseases related to Mixed Phenotype Acute Leukemia:



Diseases related to Mixed Phenotype Acute Leukemia

Symptoms & Phenotypes for Mixed Phenotype Acute Leukemia

GenomeRNAi Phenotypes related to Mixed Phenotype Acute Leukemia according to GeneCards Suite gene sharing:

26 (show all 28)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.83 DNTT
2 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.83 MPO
3 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.83 DNTT
4 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.83 DNTT
5 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.83 SETBP1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.83 ABL1 DNTT
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.83 ABL1 DNTT MPO SETBP1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.83 DNTT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.83 SETBP1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.83 DNTT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-184 9.83 MPO
12 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.83 SETBP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.83 SETBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.83 SETBP1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.83 ABL1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.83 MPO
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.83 ABL1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.83 ABL1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-40 9.83 MPO
20 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.83 ABL1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.83 ABL1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.83 MPO
23 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.83 MPO
24 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.83 MPO
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.83 DNTT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.83 SETBP1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.83 SETBP1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.83 ABL1

MGI Mouse Phenotypes related to Mixed Phenotype Acute Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 ABL1 ANPEP CD7 DNMT3A DNTT ERCC2
2 homeostasis/metabolism MP:0005376 10.03 ABL1 CDH1 DNMT3A DNTT ERCC2 FGFR1
3 endocrine/exocrine gland MP:0005379 10.02 ABL1 ANPEP CD7 CDH1 DNMT3A ERCC2
4 immune system MP:0005387 9.97 ABL1 ANPEP CD7 CDH1 DNMT3A DNTT
5 mortality/aging MP:0010768 9.73 ABL1 CDH1 DNMT3A ERCC2 FGFR1 KDM4C
6 neoplasm MP:0002006 9.1 CDH1 ERCC2 KDM4C KMT2A MSH6 WT1

Drugs & Therapeutics for Mixed Phenotype Acute Leukemia

Drugs for Mixed Phenotype Acute Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
2
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
3 Triamcinolone diacetate Phase 3
4 triamcinolone acetonide Phase 3
5 Triamcinolone hexacetonide Phase 3
6
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
7
rituximab Approved Phase 2 174722-31-7 10201696
8
Idarubicin Approved Phase 2 58957-92-9 42890
9
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
10
Ipilimumab Approved Phase 2 477202-00-9
11
nivolumab Approved Phase 2 946414-94-4
12
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
13
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
14
midostaurin Approved, Investigational Phase 2 120685-11-2 104937 9829523
15
Melphalan Approved Phase 2 148-82-3 460612 4053
16
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
17
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
18
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
19
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
20
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
22
Ichthammol Approved Phase 2 8029-68-3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
24
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
25
Mercaptopurine Approved Phase 2 50-44-2 667490
26
Daunorubicin Approved Phase 2 20830-81-3 30323
27
Lenograstim Approved, Investigational Phase 2 135968-09-1
28
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
29
Busulfan Approved, Investigational Phase 2 55-98-1 2478
30
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
31
Pegaspargase Approved, Investigational Phase 2 130167-69-0
32
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
33
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
34
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
35
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
36
Thioguanine Approved Phase 2 154-42-7 2723601
37
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
38
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
39 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
40
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
41
tannic acid Approved Phase 2 1401-55-4
42
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
43
Mesna Approved, Investigational Phase 2 3375-50-6 598
44
Blinatumomab Approved, Investigational Phase 2 853426-35-4
45
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
46
leucovorin Approved Phase 2 58-05-9 6006 143
47
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
48
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
49
Mycophenolic acid Approved Phase 2 24280-93-1 446541
50
Decitabine Approved, Investigational Phase 2 2353-33-5 451668

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Recruiting NCT03959085 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Leucovorin;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine;Vincristine Sulfate
2 Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease Recruiting NCT01951885 Phase 3 tacrolimus;methotrexate;Mycophenolate mofetil;Methotrexate (low dose)
3 Giving CAR-T CD19 Transgenic T Cells for Acute Myeloid Leukemia Patients (AML) With t 8:21 and CD19 Expression Not yet recruiting NCT04257175 Phase 2, Phase 3
4 A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) Completed NCT02044796 Phase 1, Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride
5 A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
6 Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) Completed NCT02921061 Phase 1, Phase 2 Cladribine;Cytarabine;Decitabine;Mitoxantrone Hydrochloride
7 Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia Completed NCT00990249 Phase 2 Busulfan;Clofarabine;Thymoglobulin
8 AUGMENT-101: A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX 5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation Recruiting NCT04065399 Phase 1, Phase 2 SNDX-5613
9 A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Recruiting NCT02135874 Phase 2 Clofarabine;Cytarabine;Dexamethasone;Idarubicin;Sorafenib;Sorafenib Tosylate;Vincristine;Vincristine Sulfate
10 A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Recruiting NCT03267186 Phase 2 Ibrutinib
11 A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell ALL, and Mixed Phenotype Acute Leukemia Recruiting NCT04128501 Phase 2 Azacitidine;Venetoclax
12 A Phase II Randomized Controlled Trial Comparing Four GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. CD34+-Selected Pan T Cell Depletion (CD34+) vs. Post-Transplantation Cyclophosphamide (PTCy) vs. Tacrolimus and Methotrexate (TacMTX) PBSCT Recruiting NCT03970096 Phase 2 Thiotepa;Fludarabine;Tacrolimus;Methotrexate;Anti-Thymocyte Globulin;Cyclophosphamide;Cyclosporine;Sirolimus
13 Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Recruiting NCT01028716 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus;Fludarabine
14 Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen Recruiting NCT00719888 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine;Mycophenolate Mofetil;Thiotepa
15 Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML Recruiting NCT02115295 Phase 2 Cladribine;Cytarabine;Gilteritinib;Idarubicin;Midostaurin;Venetoclax
16 A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Recruiting NCT03128034 Phase 1, Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
17 Addition of Sorafenib to G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study Recruiting NCT02728050 Phase 1, Phase 2 Cladribine;Cytarabine;Mitoxantrone;Sorafenib
18 Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults Recruiting NCT03779854 Phase 2 Thiotepa;Fludarabine;Cyclophosphamide;Busulfan;Tacrolimus;Methotrexate
19 Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study Recruiting NCT03012672 Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride
20 Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies Recruiting NCT04191187 Phase 2 Fludarabine;Melphalan
21 Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML Recruiting NCT03683433 Phase 2 Azacitidine;Enasidenib Mesylate
22 Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia Recruiting NCT02799147 Phase 1, Phase 2 Fludarabine monophosphate;Busulfan;Bendamustine
23 A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT03404193 Phase 2 Decitabine;Venetoclax
24 A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)) Recruiting NCT04047641 Phase 2 Cladribine;Cytarabine;Idarubicin;Quizartinib
25 Personalized NK Cell Therapy in Cord Blood Transplantation Recruiting NCT02727803 Phase 2 Busulfan;Clofarabine;Cyclophosphamide;Fludarabine Phosphate;Melphalan
26 Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment Recruiting NCT03096782 Phase 2 Busulfan;Clofarabine;Cyclophosphamide;Fludarabine;Melphalan;Mycophenolate Mofetil;Tacrolimus
27 An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-Azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (> 65 Years) Patients Recruiting NCT02397720 Phase 2 Azacitidine
28 Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Treosulfan Based Preparative Regimen Active, not recruiting NCT00796068 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Treosulfan
29 Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies Active, not recruiting NCT01690520 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Thiotepa
30 A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement Active, not recruiting NCT02828358 Phase 2 Azacitidine;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Hydrocortisone Sodium Succinate;Leucovorin;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine;Vincristine Sulfate
31 A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children Active, not recruiting NCT01858740 Phase 2 Fludarabine Phosphate;Methotrexate;Tacrolimus;Thiotepa
32 A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies Active, not recruiting NCT02793544 Phase 2 Fludarabine;Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;Busulfan;Cyclophosphamide 50mg/kg/day IV on Days -2,-1;Cyclophosphamide 50mg/kg/day IV on Days -5,-4;Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;Sirolimus;Mycophenolate mofetil;G-CSF;Pre-HCT Mesna on Days -6 and -5;Pre-HCT Mesna on Days -2 and -1;Pre-HCT Mesna on Days -5 and -4;Post-HCT Mesna
33 A Prospective, Single Arm, Open Label, Clinical Trial to Evaluate the Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage Not yet recruiting NCT04440267 Phase 2 vincristine;daunorubicin;cyclophosphamide;L-Asparaginase;prednisone;mercaptopurine;methotrexate;dexamethasone;Tyrosine kinase inhibitor
34 A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies Not yet recruiting NCT03739606 Phase 2
35 A Phase 2, Multicenter, Single Arm Trial to Assess the Safety and Efficacy of a Pediatric Approach to for Young Adults With Acute Lymphoblastic Leukemia With Blinatumomab Therapy for High-risk Patients Prior to Allogeneic Transplantation Not yet recruiting NCT04334993 Phase 2 Blinatumomab
36 A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD Suspended NCT02220985 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Methotrexate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
37 An Open-Label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia Terminated NCT02399917 Phase 2 Azacitidine
38 Management of Venous Thromboembolic Events (VTE) in Patients With Hematologic Disorders and Treatment-Induced Thrombocytopenia: A Pilot Study Terminated NCT03195010 Phase 2
39 A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated NCT02419755 Phase 2 Bortezomib;Vorinostat;Mitoxantrone;Cytarabine;Methotrexate;Hydrocortisone;Peg-L-Asparaginase;Erwinia L-Asparaginase;Dexamethasone;Mercaptopurine;Doxorubicin
40 Infusion of Off the Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (NLA101) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies Withdrawn NCT03399773 Phase 2 Cyclophosphamide;Fludarabine;Thiotepa
41 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Withdrawn NCT02718755 Phase 2 Fludarabine;Cytarabine;Erwinase
42 A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed NCT02212561 Phase 1 Selinexor;Fludarabine;Cytarabine;methotrexate/hydrocortisone/cytarabine
43 A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008) Completed NCT02270788 Phase 1 Crenolanib;Sorafenib;methotrexate, hydrocortisone and cytarabine with leucovorin
44 A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Recruiting NCT02879695 Phase 1
45 A Phase I and Expansion Cohort Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia Recruiting NCT03194932 Phase 1 Venetoclax;Cytarabine;Idarubicin;Intrathecal Triple Therapy
46 Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Recruiting NCT03326921 Phase 1 Fludarabine
47 Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT02159495 Phase 1 cyclophosphamide;Fludarabine Phosphate
48 Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies Recruiting NCT03843528 Phase 1 Vorinostat;Azacitidine Injection
49 CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies Active, not recruiting NCT02529813 Phase 1 Cyclophosphamide;Fludarabine Phosphate
50 Natural Killer Cells in Allogeneic Cord Blood Transplantation Active, not recruiting NCT01619761 Phase 1 Cyclophosphamide;Fludarabine Phosphate;Lenalidomide;Melphalan;Mycophenolate Mofetil;Tacrolimus

Search NIH Clinical Center for Mixed Phenotype Acute Leukemia

Cochrane evidence based reviews: leukemia, biphenotypic, acute

Genetic Tests for Mixed Phenotype Acute Leukemia

Genetic tests related to Mixed Phenotype Acute Leukemia:

# Genetic test Affiliating Genes
1 Biphenotypic Acute Leukaemia 29

Anatomical Context for Mixed Phenotype Acute Leukemia

MalaCards organs/tissues related to Mixed Phenotype Acute Leukemia:

40
Myeloid, T Cells, B Lymphoblasts, Bone Marrow, Bone, Testes, Nk Cells

Publications for Mixed Phenotype Acute Leukemia

Articles related to Mixed Phenotype Acute Leukemia:

(show top 50) (show all 188)
# Title Authors PMID Year
1
Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia. 61
32196814 2020
2
Mixed phenotype acute leukemia: Biological profile, clinical characteristic and treatment outcomes: Report of the population-based study. 61
32223036 2020
3
Prognostic impact of Philadelphia Chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome. 61
32419244 2020
4
Mixed Phenotype Acute Leukemia that Evolved from Myelodysplastic Syndrome with Excess Blasts. 61
31504737 2020
5
A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML. 61
32561191 2020
6
Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab. 61
32375465 2020
7
Optimal therapeutic strategies for mixed phenotype acute leukemia. 61
31913151 2020
8
An Original Complex Rearrangement Involving Chromosomes 9, 11, and 14, Harboring a Complex KMT2A Gene Rearrangement in an Infant With Mixed-phenotype Acute Leukemia. 61
32134839 2020
9
[CAR-T cell therapy for mixed phenotype acute leukemia: a case report]. 61
32311901 2020
10
Microgranular acute promyelocytic leukemia with expression of T-cell markers mimicking mixed-phenotype acute leukemia. 61
32163562 2020
11
Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. 61
31661160 2020
12
Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. 61
32060402 2020
13
18F-FDG PET/CT in Graft Versus Host Disease-Associated Polymyositis. 61
31693622 2020
14
T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. 61
32099038 2020
15
Longitudinal whole-genome sequencing reveals the evolution of MPAL. 61
31786363 2020
16
[Pneumatosis cystoides intestinalis developing subsequent to allogeneic hematopoietic stem cell transplantation for mixed phenotype acute leukemia]. 61
32378572 2020
17
ETP/Myeloid Mixed Phenotype Acute Leukemia: A Provisional Entity. 61
32158113 2020
18
Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation. 61
30614203 2020
19
Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. 61
31792411 2019
20
Phlegmonous gastritis in a patient with mixed-phenotype acute leukemia in the neutropenia phase during chemotherapy: A case report. 61
31702630 2019
21
Patient with mixed-phenotype acute leukemia with CBFB rearrangement. 61
31012358 2019
22
Acute Leukemias of Ambiguous Lineage: Clarification on Lineage Specificity. 61
31352981 2019
23
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. 61
30707502 2019
24
[Genetic characteristics and prognosis of mixed phenotype acute leukemia]. 61
32397026 2019
25
Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia. 61
31388256 2019
26
Multiparameter Flow Cytometry Applications in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL). 61
31321906 2019
27
Acute leukemia in a patient with 15q overgrowth syndrome. 61
30861314 2019
28
Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma. 61
30578714 2019
29
Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis. 61
30769192 2019
30
Early Deaths in Pediatric Acute Leukemia: A Major Challenge in Developing Countries. 61
30615014 2019
31
Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. 61
31033213 2019
32
[Clinical Characteristics of Patients with Ph+ Mixed Phenotype Acute Leukemia]. 61
30998137 2019
33
Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. 61
30786841 2019
34
Xiao W, Bharadwaj M, Levine M, et al. PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. Blood Adv. 2018;2(23):3526-3539. 61
30926597 2019
35
Mixed-phenotype acute leukemia with t(4;11)(q21;q23) KMT2A-AFF1-rearranged. 61
30872272 2019
36
Biphenotypic acute leukemia or acute leukemia of ambiguous lineage in childhood: clinical characteristics and outcome. 61
30956966 2019
37
Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab. 61
30328137 2019
38
Myeloid/Lymphoid Neoplasm With FGFR1 Rearrangement Accompanying RUNX1 and NOTCH1 Gene Mutations. 61
31824864 2019
39
Mixed Phenotype Acute Leukemia, B/Myeloid with t(9;22): Diagnostic and Therapeutic Challenges. 61
30828170 2019
40
Clinical Characteristics And Outcome Of Biphenotypic Acute Leukemia: 10 Case Reports And Literature Review. 61
31802948 2019
41
Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions. 61
30255571 2019
42
CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice. 61
31141090 2019
43
Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia. 61
31885955 2019
44
T-lymphoid/myeloid mixed phenotype acute leukemia and early T-cell precursor lymphoblastic leukemia similarities with NOTCH1 mutation as a good prognostic factor. 61
31118806 2019
45
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. 61
30530780 2018
46
Lineage switch from acute myeloid leukemia to T cell/myeloid mixed phenotype acute leukemia: First report of an adult case. 61
30203419 2018
47
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. 61
30117174 2018
48
Mixed-phenotype acute leukemia characteristics: first report from Iran. 61
30019150 2018
49
Mixed-phenotype acute leukemia, T/megakaryoblastic. 61
30498070 2018
50
Rapid diagnosis of mixed phenotype acute leukemia after identifying a blood histogram abnormality. 61
30009244 2018

Variations for Mixed Phenotype Acute Leukemia

Expression for Mixed Phenotype Acute Leukemia

Search GEO for disease gene expression data for Mixed Phenotype Acute Leukemia.

Pathways for Mixed Phenotype Acute Leukemia

Pathways related to Mixed Phenotype Acute Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 MSH6 MPO FGFR1 CDH1 ABL1
2 11.5 MPO CD33 ANPEP
3 10.92 DNTT CD7 CD33 ANPEP
4 10.59 MSH6 MPO ERCC2

GO Terms for Mixed Phenotype Acute Leukemia

Cellular components related to Mixed Phenotype Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 WT1 U2AF1 SETBP1 PHF6 MSH6 MPO
2 nucleoplasm GO:0005654 9.47 WT1 U2AF1 SETBP1 PHF6 MSH6 MPO
3 euchromatin GO:0000791 9.16 DNTT DNMT3A

Biological processes related to Mixed Phenotype Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to oxidative stress GO:0006979 9.33 MPO ERCC2 ABL1
2 regulation of gene expression GO:0010468 9.26 KDM4C FGFR1 DNMT3A CDH1
3 negative regulation of cell-cell adhesion GO:0022408 8.62 CDH1 ABL1

Molecular functions related to Mixed Phenotype Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.61 WT1 SETBP1 PHF6 MSH6 KMT2A ERCC2
2 metal ion binding GO:0046872 9.4 WT1 U2AF1 PHF6 MPO KMT2A KDM4C
3 four-way junction DNA binding GO:0000400 9.16 MSH6 ABL1

Sources for Mixed Phenotype Acute Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....